IRIS
COLUCCI, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.072
AS - Asia 2.941
EU - Europa 2.414
SA - Sud America 690
AF - Africa 109
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 6
Totale 15.238
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.994
SG - Singapore 1.339
CN - Cina 813
BR - Brasile 619
HK - Hong Kong 454
SE - Svezia 454
DE - Germania 446
RU - Federazione Russa 355
IT - Italia 284
UA - Ucraina 258
FI - Finlandia 179
GB - Regno Unito 150
VN - Vietnam 125
FR - Francia 123
CI - Costa d'Avorio 63
IN - India 55
IE - Irlanda 41
CA - Canada 35
BD - Bangladesh 34
AR - Argentina 30
PL - Polonia 26
MX - Messico 25
BE - Belgio 23
ZA - Sudafrica 22
TR - Turchia 19
EC - Ecuador 16
NL - Olanda 16
ID - Indonesia 15
JP - Giappone 14
IQ - Iraq 12
PK - Pakistan 12
AT - Austria 11
ES - Italia 11
LT - Lituania 10
VE - Venezuela 9
EG - Egitto 8
CZ - Repubblica Ceca 6
PY - Paraguay 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
AU - Australia 5
DO - Repubblica Dominicana 5
IL - Israele 5
JO - Giordania 5
KR - Corea 5
SM - San Marino 5
IR - Iran 4
MA - Marocco 4
SA - Arabia Saudita 4
CL - Cile 3
EU - Europa 3
GR - Grecia 3
KZ - Kazakistan 3
TN - Tunisia 3
UY - Uruguay 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AZ - Azerbaigian 2
CO - Colombia 2
CR - Costa Rica 2
ET - Etiopia 2
JM - Giamaica 2
KE - Kenya 2
KG - Kirghizistan 2
KW - Kuwait 2
MY - Malesia 2
NI - Nicaragua 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CM - Camerun 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
GD - Grenada 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
LU - Lussemburgo 1
MD - Moldavia 1
MN - Mongolia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PE - Perù 1
RO - Romania 1
RS - Serbia 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
VC - Saint Vincent e Grenadine 1
ZM - Zambia 1
Totale 15.238
Salva come PNG Salva come JPEG
Città #
Fairfield 1.157
Woodbridge 1.028
Ashburn 787
Houston 697
Singapore 675
Chandler 666
Jacksonville 607
Seattle 504
Hong Kong 451
Cambridge 412
Ann Arbor 397
Wilmington 386
Nyköping 380
Beijing 248
Roxbury 161
Lawrence 159
Nanjing 158
Des Moines 95
Bari 92
New York 92
Dallas 90
Boardman 88
Los Angeles 74
Abidjan 63
Princeton 62
San Diego 61
São Paulo 60
Brooklyn 55
Inglewood 52
Ho Chi Minh City 50
Strasbourg 48
Hebei 42
Nanchang 41
Shenyang 40
Dublin 39
Santa Clara 39
Grafing 37
London 33
Buffalo 31
Tianjin 25
Brussels 23
Chicago 23
Helsinki 22
Frankfurt am Main 21
Jiaxing 21
Belo Horizonte 20
Changsha 20
Dearborn 20
Hanoi 20
Moscow 20
Warsaw 20
Atlanta 18
Boston 18
Paris 17
Pune 17
Munich 16
Rio de Janeiro 16
Johannesburg 14
Mexico City 13
Guangzhou 12
Milan 12
Poplar 12
Tokyo 12
Denver 11
Montreal 11
Orem 11
San Francisco 11
Auburn Hills 10
Curitiba 10
Dhaka 10
Manchester 10
Redwood City 10
Toronto 10
Brasília 9
Campinas 9
Kunming 9
San Mateo 9
Stockholm 9
Amsterdam 8
Augusta 8
Falkenstein 8
Jakarta 8
Jinan 8
Phoenix 8
Rome 8
Secaucus 8
Zhengzhou 8
Caxias do Sul 7
Mumbai 7
Quito 7
Vienna 7
Charlotte 6
Chennai 6
Council Bluffs 6
Düsseldorf 6
Foggia 6
Genoa 6
Guarulhos 6
Porto Alegre 6
Salt Lake City 6
Totale 10.892
Salva come PNG Salva come JPEG
Nome #
Platelet drop and fibrinolytic shutdown in patients with sepsis 175
Fisiologia dell'Emostasi 175
Factor IX-Padua enhances the fibrinolytic resistance of plasma clots 171
Histones differentially modulate the anticoagulant and profibrinolytic activities of heparin, heparin derivatives and dabigatran. 165
Coagulation activation is associated with nicotinamide adenine dinucleotide phosphate oxidase-dependent reactive oxygen species generation in hemodialysis patients. 156
Coagulopathy of Acute Sepsis 155
Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation 148
A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression 147
Influence of cell-associated tissue factor concentration on the anticoagulant activity of dabigatran. A possible explanation for the reduced incidence of intracranial bleeding 146
FVIII/VWF complex displays a greater pro-hemostatic activity than FVIII preparations devoid of VWF. Study in plasma and cell-based models 146
Antithrombotic activity of 12 table grape varieties. Relationship with polyphenolic profile 145
A modified prothrombin time to measure the anticoagulant activity of dabigatran 143
Changes in coagulation-fibrinolysis balance in blood mononuclear cells and in gastric mucosa from patients with Helicobacter pylori infection 141
Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors 141
Grape intake reduces thrombin generation and enhances plasma fibrinolysis. Potential role of circulating procoagulant microparticles 141
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation 135
Cultured human endothelial cells generate tissue factor in response to endotoxin 133
Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells 130
Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism 130
Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor 129
Effect of ochratoxin A on prothrombotic and proinflammatory activities of stimulated blood mononuclear cells 127
Blood and tissue fibrinolytic profile in patients with colorectal cancer 127
Platelets and fibrinolysis 127
Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway 126
Gene expression signature induced by grape intake in healthy subjects reveals wide-spread beneficial effects on peripheral blood mononuclear cells 126
Co-administration of low molecular weight heparin enhances the profibrinolytic effect of warfarin through different mechanisms. 125
Hyperprothrombinemia-induced APC resistance: differential influence on fibrin formation and fibrinolysis 125
In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis. Study in healthy subjects and correlation with blood fibrinolytic parameters 124
CHANGES IN THE COAGULATION-FIBRINOLYSIS BALANCE OF ENDOTHELIAL-CELLS AND MONONUCLEAR PHAGOCYTES - ROLE IN DISSEMINATED INTRAVASCULAR COAGULATION ASSOCIATED WITH INFECTIOUS-DISEASES 123
Tissue factor in health and disease 122
Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots 122
Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis 121
Cultured human mesangial cells produce both type 1 and type 2 plasminogen activator inhibitors 120
Sepsis, thrombosis and organ dysfunction 118
Helicobacter pylori neutrophil-activating protein stimulates tissue factor and plasminogen activator inhibitor-2 production by human blood mononuclear cells 118
D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis 118
Low D-dimer levels in sepsis: Good or bad? 117
Reduced generation of procoagulant activity by endotoxin-stimulated mononuclear cells from patients with chronic myeloid leukaemia. 115
Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation 114
Role of leucocyte procoagulant activity in endotoxin-induced DIC: evidence from comparative studies in rats and rabbits. 114
Anomalie cellulari e plasmatiche della coagulazione e della fibrinolisi dei linfomi ed effetto della terapia 114
Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein. 113
A hitherto undescribed defect of platelet coagulant activity in polycythaemia vera and essential thrombocythaemia. 113
Cancer cell procoagulant activity: evaluation by an amidolytic assay. 112
Cancer cell procoagulant: a novel vitamin K-dependent activity. 112
TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival 110
A ROLE FOR PLATELETS AND THROMBIN IN THE JUVENILE STROKE OF 2 SIBLINGS WITH DEFECTIVE THROMBIN-ADSORBING CAPACITY OF FIBRIN(OGEN) 110
Thrombolysis enhancing activity of a low molecular weight dermatan sulfate (Desmin 370) in experimental pulmonary embolism in rats. 110
ENHANCED ENDOTHELIAL TISSUE FACTOR BUT NORMAL THROMBOMODULIN IN ENDOTOXIN-TREATED RABBITS. 110
Fibrin down-regulates LPS- and PMA- induced tissue factor expression by blood mononuclear cells 108
Cellular coagulation-fibrinolysis balance and atherosclerosis 106
In vitro inhibition of monocyte tissue factor and PAI-2 production by Ochratoxin A 106
Stroke in two young siblings with congenital dysfibrinogenemia. 106
Monocytes, but not endothelial cells, downregulate the anticoagulant activity of activated protein C 104
Cellular and plasmatic anomalies of the coagulation system and fibrinolysis in children with lymphomas and influence of cytostatic treatment 104
Evidence that fibrynolitic changes in paediatric obesity translate in a hypofibrinolytic state. Relative contribution of TAFI and PAI-1 104
Complement-dependent and complement-independent interactions of bacterial lipopolysaccharides and mucopeptides with rabbit and human platelets. 103
Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential 103
FAILURE OF WARFARIN TO AFFECT THE TISSUE FACTOR ACTIVITY AND THE METASTATIC POTENTIAL OF MURINE FIBRO-SARCOMA CELLS. 103
Unbalanced coagulation-fibrinolysis potential during L-Asparaginase therapy in children with acute lymphoblastic leukaemia 103
Effect of Ochratoxin A on prothrombotic and proinflammatory activities of stimulated blood mononuclear cells 103
Treatment with cyclosporin A does not affect macrophage procoagulant activity and plasminogen activator inhibitor in mice 102
Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency. 101
Procoagulant activity of sarcoma sublines with different metastatic potential 99
Does inhibiting Sur1 complement rtPA in cerebral ischemia? 99
NOVEL GLUCOSE-CONJUGATED HIGHLY POTENT DUAL THROMBIN AND FACTOR Xa INHIBITORS AS POTENTIAL ANTITHROMBOTICS 99
Reduction of the plasma levels of tissue plasminogen activator after infusion of a lipid emulsion in humans 99
The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood 99
URINARY PROCOAGULANT AND FIBRINOLYTIC-ACTIVITY IN HUMAN GLOMERULONEPHRITIS - RELATIONSHIP WITH RENAL-FUNCTION 98
Increased mononuclear cell tissue factor and type-2 plasminogen activator inhibitor and reduced plasma fibrinolytic capacity in children with lymphoma 98
Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies 98
Estressione del tisuue factor e del vasular endothelial growth factor nel carcinoma del colon retto 98
Expression of tissue factor and vascular endothelial growth factor in colorectal carcinoma 98
Extracellular histones promote fibrinolysis by single-chain urokinase-type plasminogen activator in a factor seven activating protease-dependent way 98
REDUCED FIBRINOLYTIC-ACTIVITY IN GLOMERULI ISOLATED FROM RABBITS INFUSED WITH TUMOR-NECROSIS-FACTOR. 96
Alterazioni dell'equilibrio coagulativo-fibrinolitico dei monociti e della capacità fibrinolitica plasmatica dei linfomi 96
Ochratoxin A inhibits the production of tissue factor and plasminogen activator inhibitor-2 by human blood mononuclear cells: Another potential mechanism of immune-suppression 96
Increased macrophage procoagulant activity but normal endothelial thrombomodulin in rabbits fed an atherogenic diet 95
Helicobacter pylori neutrophil activating protein stimulates tissue factor and plasminogen inhibitor-2 production by human blood mononuclear cells 95
Early increase of a new platelet coagulant activity in rats fed a thrombogenic diet. 95
Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. 94
Alterazioni dell'equilibrio coagulativo-fibrinolitico dei monociti e della capacità fibrinolitica plasmatica nei linfomi 94
Generation of procoagulant activity by mononuclear phagocytes: a possible mechanism contributing to blood clotting activation within malignant tissues. 93
Skin extracts from 2 italian table grapes (italia and palieri) inhibit tissue factor expression by human blood mononuclear cells 92
The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation. 92
Procoagulant properties of bare and highly-PEGylated vinyl-modified silica nanoparticles 92
EXPERIMENTAL ENDOTOXEMIA AS A MODEL OF IMPAIRED FIBRINOLYSIS 90
Rebuttal to: Effect of heparin on TAFI-dependent inhibition of fibrinolysis 90
HEMOSTATIC VARIABLES IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA - EFFECT OF REGULAR PLASMA-CHOLESTEROL REMOVAL BY LOW-DENSITY-LIPOPROTEIN APHERESIS 90
Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis 89
Retinoids inhibit the respiratory burst and degranulation of stimulated human polymorphonuclear leukocytes 89
Thrombin Activatable Fibrinolysis Inhibitor: at the nexus of fibrinolysis and inflammation 88
Coagulation-fibrinolysis changes during off-pump bypass: effect of two heparin doses 87
Evidence that cells from experimental tumours can activate coagulation factor X. British journal of cancer. 86
An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia 86
Retinoic acid stimulates plasminogen activator inhibitor 2 production by blood mononuclear cells and inhibits urokinase-induced extracellular proteolysis 85
Prevention and therapy of experimental venous thrombosis in rabbits by desmin 370 85
Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA 85
PLASMINOGEN ACTIVATOR INHIBITOR IN THE BLOOD OF PATIENTS WITH CORONARY-ARTERY DISEASE. 84
NOVEL GLUCOSE-CONJUGATED HIGHLY POTENT DUAL THROMBIN AND FACTOR Xa INHIBITORS AS POTENTIAL ANTITHROMBOTICS 84
Totale 11.272
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.642
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.642
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021849 0 0 0 0 0 90 112 146 168 201 81 51
2021/20221.168 57 200 11 40 60 50 63 53 80 62 199 293
2022/20231.795 263 191 134 163 211 233 23 169 326 13 35 34
2023/2024463 59 102 15 35 29 102 15 21 5 10 18 52
2024/20252.482 78 32 213 100 46 181 162 244 93 103 369 861
2025/20262.426 701 221 300 586 554 64 0 0 0 0 0 0
Totale 15.348